These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18046426)

  • 1. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells.
    Huang D; Pereboev AV; Korokhov N; He R; Larocque L; Gravel C; Jaentschke B; Tocchi M; Casley WL; Lemieux M; Curiel DT; Chen W; Li X
    Gene Ther; 2008 Feb; 15(4):298-308. PubMed ID: 18046426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
    Kuzmin AI; Galenko O; Eisensmith RC
    Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues.
    Yang Y; Su Q; Grewal IS; Schilz R; Flavell RA; Wilson JM
    J Virol; 1996 Sep; 70(9):6370-7. PubMed ID: 8709265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.
    Kay MA; Meuse L; Gown AM; Linsley P; Hollenbaugh D; Aruffo A; Ochs HD; Wilson CB
    Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4686-91. PubMed ID: 9114052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th2-dependent B cell responses in the absence of CD40-CD40 ligand interactions.
    Chirmule N; Tazelaar J; Wilson JM
    J Immunol; 2000 Jan; 164(1):248-55. PubMed ID: 10605018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions.
    Chirmule N; Raper SE; Burkly L; Thomas D; Tazelaar J; Hughes JV; Wilson JM
    J Virol; 2000 Apr; 74(7):3345-52. PubMed ID: 10708452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus.
    Chen CR; Aliesky HA; Guo J; Rapoport B; McLachlan SM
    Thyroid; 2006 May; 16(5):427-34. PubMed ID: 16756463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
    Liu Y; Xia D; Li F; Zheng C; Xiang J
    Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha.
    Zhang W; Chen Z; Li F; Kamencic H; Juurlink B; Gordon JR; Xiang J
    Immunology; 2003 Feb; 108(2):177-88. PubMed ID: 12562326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
    Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
    J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine encoding CD40 targeted to dendritic cells in situ prevents the development of Heymann nephritis in rats.
    Wang Y; Wang YM; Wang Y; Zheng G; Zhang GY; Zhou JJ; Tan TK; Cao Q; Hu M; Watson D; Wu H; Zheng D; Wang C; Lahoud MH; Caminschi I; Harris DC; Alexander SI
    Kidney Int; 2013 Feb; 83(2):223-32. PubMed ID: 23223173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peptide containing a novel FPGN CD40-binding sequence enhances adenoviral infection of murine and human dendritic cells.
    Richards JL; Abend JR; Miller ML; Chakraborty-Sett S; Dewhurst S; Whetter LE
    Eur J Biochem; 2003 May; 270(10):2287-94. PubMed ID: 12752448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
    Kikuchi T; Moore MA; Crystal RG
    Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted gene therapy with CD40Ig to induce long-term acceptance of liver allografts.
    Chang GJ; Liu T; Feng S; Bedolli M; O'rourke RW; Schmidt G; Roberts JP; Stock PG
    Surgery; 2002 Aug; 132(2):149-56. PubMed ID: 12219005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus.
    Stein CS; Pemberton JL; van Rooijen N; Davidson BL
    Gene Ther; 1998 Apr; 5(4):431-9. PubMed ID: 9614566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
    Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
    J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.
    Schowalter DB; Himeda CL; Winther BL; Wilson CB; Kay MA
    J Virol; 1999 Jun; 73(6):4755-66. PubMed ID: 10233936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.